Author Interviews, Diabetes, Environmental Risks / 24.06.2024

MedicalResearch.com Interview with: Todd Hagobian, Ph.D. pronouns he/him/his Department Chair & Professor, Kinesiology and Public Health Cal Poly, San Luis Obispo, CA MedicalResearch.com: What is the background for this study? Response: Previous observational studies have shown that urinary BPA is related to Type 2 diabetes risk. Meaning, higher urinary BPA is related to an increased risk of Type 2 diabetes. However, no published study to date has determined whether several days of BPA administration (participants consume BPA) increases the risk of Type 2 diabetes. MedicalResearch.com: Where is bisphenol found?  Can exposure to bisphenol be limited in everyday life? Response:  BPA and other bisphenols are found in canned foods and plastics. BPA is one of the most widely used synthetic chemicals and we consume foods that are packed in this chemical. Most of BPA exposure comes from canned foods, and 93% of the US populations has detectable urine levels of BPA. We can limit BPA by reducing canned foods (or purchased BPA free cans) and plastic use. (more…)
Author Interviews, Diabetes, Kidney Disease / 08.06.2022

MedicalResearch.com Interview with: prof. dr. H.J. (Hiddo) Lambers Heerspink Clinical Pharmacologist Department Clinical Pharmacy and Pharmacology University Medical Center Groningen Groningen  MedicalResearch.com:  What is the background for this study?    Response: Tirzepatide is a novel GIP-GLP1 receptor agonist recently FDA approved for the treatment of type 2 diabetes. The SURPASS_4 trial demonstrated that in patients with type 2 diabetes at high cardiovascular risk tirzepatide compared to insulin glargine markedly reduces Hba1c and body weight. About 1 out of 3 patients with type 2 diabetes and CV disease has kidney disease and these patients are at high risk of kidney failure. The aim of this study was to assess whether tirzepatide could slow CKD progression in high risk individuals with type 2 diabetes participating in the SURPASS 4 trial.  (more…)
Author Interviews, CDC, Diabetes, Social Issues / 30.06.2021

MedicalResearch.com Interview with: Yu Chen, Ph.D. Prevention Effectiveness Fellow Division of Diabetes Translation CDC MedicalResearch.com: What is the background for this study? Response: Overall prevalence of diabetes has increased over the past two decades in the US, disproportionately affecting populations with low-income. The age-adjusted prevalence of diagnosed diabetes among adults aged 18 years or older increased from 6.4% in 1999−2002 to 9.4% in 2013−2016. Between 2011 and 2014, compared with persons with high income, the relative percentage increase in diabetes prevalence was 40.0%, 74.1%, and 100.4% for those classified as middle income, near poor and poor, respectively. However, recent changes in income-related inequalities in diabetes prevalence are unknown. (more…)
Author Interviews, Diabetes, JAMA / 17.06.2020

MedicalResearch.com Interview with: Richard E. Pratley, MD AdventHealth Samuel E. Crockett Chair in Diabetes Research Medical Director | AdventHealth Diabetes Institute Senior Investigator and Diabetes Program Lead AdventHealth Translational Research Institute  MedicalResearch.com: What is the background for this study? Response: Historically, older individuals with T1D have been underrepresented or excluded from clinical trials. Older individuals with T1D are at particularly high risk for hypoglycemia. Because of their long duration of diabetes, they often have impaired counterregulatory responses and hypoglycemia unawareness. Hypoglycemia in older individuals is particularly dangerous because it can lead to falls and fractures, cognitive impairment and cardiovascular events, including death. There has been the misperception that older individuals are less able to use technology to manage their diabetes.  This study dispelled that notion.   (more…)